Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 in relapsed or refractory CLL/SLL
2025-522242-49-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of CN201 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Number of participants who experience dose-limiting toxicity, Number of participants who experience an adverse event and 2 more. Planned start Oct 2026; status: authorised.
02
Drugs
CN201
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-522242-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522242-49-00.